Antimicrobial prophylaxis and the prevention of surgical site infection in cardiac surgery: an analysis of 21 007 patients in Switzerland†.
Aged
Anti-Bacterial Agents
/ administration & dosage
Antibiotic Prophylaxis
Cardiac Surgical Procedures
Cefuroxime
/ administration & dosage
Drug Combinations
Female
Humans
Male
Middle Aged
Prospective Studies
Surgical Wound Infection
/ prevention & control
Switzerland
Time Factors
Vancomycin
/ administration & dosage
Cardiac surgery
Infection control
Modelling
Prevention
Surgical antimicrobial prophylaxis
Surgical site infection
Journal
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069
Informations de publication
Date de publication:
01 Oct 2019
01 Oct 2019
Historique:
received:
08
10
2018
revised:
14
01
2019
accepted:
15
01
2019
pubmed:
24
2
2019
medline:
28
10
2020
entrez:
24
2
2019
Statut:
ppublish
Résumé
Our goal was to determine the optimal timing and choice of surgical antimicrobial prophylaxis (SAP) in patients having cardiac surgery. The setting was the Swiss surgical site infection (SSI) national surveillance system with a follow-up rate of >94%. Participants were patients from 14 hospitals who had cardiac surgery from 2009 to 2017 with clean wounds, SAP with cefuroxime, cefazolin or a vancomycin/cefuroxime combination and timing of SAP within 120 min before the incision. Exposures were SAP timing and agents; the main outcome was the incidence of SSI. We fitted generalized additive and mixed-effects generalized linear models to describe effects predicting SSIs. A total of 21 007 patients were enrolled with an SSI incidence of 5.5%. Administration of SAP within 30 min before the incision was significantly associated with decreased deep/organ space SSI [adjusted odds ratio (OR) 0.73, 95% confidence interval (CI) 0.54-0.98; P = 0.035] compared to administration of SAP 60-120 min before the incision. Cefazolin (adjusted OR 0.64, 95% CI 0.49-0.84; P = 0.001) but not vancomycin/cefuroxime combination (adjusted OR 1.05, 95% CI 0.82-1.34; P = 0.689) was significantly associated with a lower risk of overall SSI compared to cefuroxime alone. Nevertheless, there were no statistically significant differences between the SAP agents and the risk of deep/organ space SSI. The results from this large prospective study provide substantial arguments that administration of SAP close to the time of the incision is more effective than earlier administration before cardiac surgery, making compliance with SAP administration easier. The choice of SAP appears to play a significant role in the prevention of all SSIs, even after adjusting for confounding variables.
Identifiants
pubmed: 30796448
pii: 5363248
doi: 10.1093/ejcts/ezz039
doi:
Substances chimiques
Anti-Bacterial Agents
0
Drug Combinations
0
Vancomycin
6Q205EH1VU
Cefuroxime
O1R9FJ93ED
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
800-806Investigateurs
Carlo Balmelli
(C)
Marie-Christine Eisenring
(MC)
Stephan Harbarth
(S)
Stefan P Kuster
(SP)
Jonas Marschall
(J)
Virginie Masserey Spicher
(VM)
Didier Pittet
(D)
Christian Ruef
(C)
Hugo Sax
(H)
Matthias Schlegel
(M)
Alexander Schweiger
(A)
Nicolas Troillet
(N)
Andreas F Widmer
(AF)
Giorgio Zanetti
(G)
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.